Back to search results

AMAZE 1: NNC0487-0111 for Excess Body Weight

This study, called AMAZE 1, is looking into whether a medicine called NNC0487-0111 is safe and effective for people who have excess body weight. You would receive weekly injections under the skin, either of NNC0487-0111 or a placebo (a treatment with no active medicine). The study aims to see how much your body weight changes over 84 weeks. To join, you must be at least 18 years old, of any gender, and have tried to lose weight unsuccessfully before. Your blood sugar levels (HbA1c) must be below 6. The study plans to enroll about 1150 people.

Study design
This is an interventional study where participants are randomly assigned to receive either NNC0487-0111 or a placebo. It aims to enroll 1150 participants.
What's involved
Participants will receive weekly subcutaneous injections in the thigh, abdomen, or upper arm for 84 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures body weight change from baseline to week 84.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07339423

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

Recruiting
PHASE3Ages 18+InterventionalTreatment
Novo Nordisk A/S
~1,150 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:NNC0487-0111Placebo (matched to NNC0487-0111)

At a glance

Recruiting sites
71 of 72 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Relative change in body weight
Measured over From baseline (week 0) to week 84

Conditions

Obesity

Explore related trials

Obesity

Where it's being run

72 sites across 32 states
United Kingdom8
Belgium6
Germany6
Argentina5
Denmark5
France5
North Carolina3
South Carolina3

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female (sex at birth).
Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion

HbA1c ≥ 6.5% (48 millimole per mole \[mmol/mol\]) as measured by the central laboratory at screening.
History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.

What this trial measures

  • Relative change in body weightFrom baseline (week 0) to week 84

    Measured as percentage of body weight.